---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-029860"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:12:28.471925+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Femasys Q2 2025 sales up 85% to $409K, net loss $4.6M, cash runway into early Q4

## Summary
- Sales $409,268 (+84.8% YoY); net loss $4.59M ($0.16/sh) vs $4.68M ($0.21/sh) prior year.
- Cash $3.2M, accumulated deficit $137.7M; expects current cash to fund ops into early Q4 2025.
- EU MDR approval for FemBloc non-surgical birth control; first $400K order from Spain.
- Australia/New Zealand approvals for FemaSeed and FemVue; partnered with Carolinas Fertility Institute.
- Closed $4.5M public offering and private placement for working capital.

## SEC filing metadata
- accession: 0001140361-25-029860
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036125029860/0001140361-25-029860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036125029860/ef20053541_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-029860
- JSON: https://secwatch.observer/filing/0001140361-25-029860.json
- Plain text: https://secwatch.observer/filing/0001140361-25-029860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.